Celularity Inc. (NASDAQ:CELU) Sees Significant Growth in Short Interest

Celularity Inc. (NASDAQ:CELU) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 1,040,000 shares, a growth of 261.9% from the February 13th total of 287,400 shares. Currently, 8.3% of the shares of the stock are short sold. Based on an average trading volume of 170,300 shares, the short-interest ratio is presently 6.1 days.

Celularity Trading Up 17.2 %

Shares of CELU opened at $1.57 on Thursday. Celularity has a 52-week low of $1.00 and a 52-week high of $6.05. The business’s fifty day moving average is $1.95 and its 200-day moving average is $2.32.

Hedge Funds Weigh In On Celularity

Several hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Investments LP bought a new position in shares of Celularity in the 4th quarter valued at $93,000. Biltmore Family Office LLC bought a new position in shares of Celularity in the 4th quarter valued at $73,000. C V Starr & Co. Inc. bought a new position in shares of Celularity in the 4th quarter valued at $1,589,000. Finally, Keynote Financial Services LLC increased its stake in shares of Celularity by 90.1% in the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock valued at $52,000 after purchasing an additional 11,863 shares during the last quarter. Institutional investors own 19.02% of the company’s stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.